
A new investigational vaccine, LASSARAB, shows promise for use against Lassa fever and rabies.

A new investigational vaccine, LASSARAB, shows promise for use against Lassa fever and rabies.

The company says the new equipment will reduce sample turnaround times and increase variant detection quality and accuracy.

Roche has acquired Tusk Therapeutics in a deal worth up to EUR 659 million (US$762 million).

The new facility will include comprehensive mammalian process development and manufacturing capabilities.

This year’s awards attracted more than 250 entries, which included innovations in products and service offerings from across the bio/pharmaceutical supply chain and honored companies and individuals driving the industry forward.

A stick-pack laminate packaging film from Amcor uses Pylote’s antimicrobial packaging technology to eliminate the need for preservatives in the liquid pharmaceutical contents.

The investment includes an upgrade and expansion of the company’s packaging and softgel encapsulation capabilities at its facility in Aprilia, Italy.

The company’s three acquisitions over the last 12 months have increased its global presence, expanding its European footprint and bringing new localized services in Asia-Pacific and the west coast of the United States.

The companies will develop and commercialize ARO-HBV, a Phase I/II subcutaneous, ribonucleic acid interference therapy candidate being investigated for the treatment of chronic hepatitis B viral infection.

The companies signed a three-year clinical manufacturing agreement to manufacture GlaxoSmithKline’s specific peptide enhanced affinity receptor T-cell receptor therapy for United States, Canadian, and European clinical trials.

At CPhI Worldwide 2018, Tom Wilson, vice president of Contract Manufacturing Operations for Pfizer Global Supply and Pfizer CentreOne Contract Manufacturing, will discuss best practices for meeting manufacturing challenges of compliance as requirements shift.

The UCL-Pall Biotech Centre of Excellence will address industry challenges and provide workforce training.

Bormioli Pharma, a provider of integrated glass and plastic containers, closures, and accessories for packaging, will showcase products at CPhI Worldwide 2018 at booth 4C20, from Oct. 9–11, 2018.

Syngene International’s Jegadeesh Thampi will discuss the significance of engineering data generation to develop robust, safe, and reproducible processes on Oct. 11, 2018 at CPhI Worldwide.

At this year’s CPhI Worldwide congress in Madrid, Spain, Archer Daniels Midland Company (ADM) will present its range of products spanning probiotics and microbiome solutions to highly purified, injectable-grade vegetable oils.

The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a consultation to seek views on how legislations and procedures of the agency may need to be modified should there be a ‘no-deal’ Brexit scenario.

Advances in biologic drug development require increased methodological and technological innovation from the biopharma industry. Learn more at the new bioLIVE launching this year adjacent to CPhI Worldwide 2018.

The new bioLIVE event, launching this year with CPhI Worldwide 2018, will explore innovation in bioprocessing and manufacturing with a focus on the roles of innovative methods and technology for biopharma continuous manufacturing.

Luxembourg-based pharmaceutical group, C2 Pharma (formerly known as Centroflora CMS) successfully validated the manufacturing process for two APIs-digoxin and digoxin micron.

During CPhI Worldwide 2018 in Madrid, Spain, DuPont will showcase fully integrated pharmaceutical and healthcare portfolios, combining those of DuPont Nutrition & Health, Dow Pharma Solutions, and FMC Health and Nutrition.

Neopac, provider of high-quality tube packaging, has announced in a press release it will introduce a new eyecare solution at CPhI’s event in Madrid, Spain from Oct. 9–11, 2018.

The agency approved Insmed’s Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease).

Lonza’s Capsugel Colorista capsule R&D solution can cut overall development time and offers greater flexibility during technical color development.

Funding from Innovate UK will be used by Medherant to support manufacture of transdermal patches for clinical trials.

The companies will work together to discover, develop, and commercialize immunotherapies for patients with solid-tumor cancers in a collaboration worth $695 million per program.

Idifarma, a Spanish contract development and manufacturing organization (CDMO) that specialises in niche and highly potent products, confirmed on Oct. 1, 2018 that its good manufacturing practice (GMP) spray drying technology for highly potent drugs is now operational.

Rentschler Fill Solutions received a certificate of GMP compliance from the Austrian Agency for Health and Food Safety for its new aseptic fill/finish facility.

Kangstem Biotech has selected Orgenesis subsidiary, MaSTherCell, as its contract manufacturing partner for the European clinical trial of Furestem-AD.

The companies partnered to build a 500-L single-use pilot-scale plant for biologics production.

Researchers who are younger than 35 years with an advanced degree and working within Europe will be able to apply for the award.